These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29763999)

  • 1. Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy.
    Yamagishi SI
    Diabetes Metab Res Rev; 2018 Oct; 34(7):e3024. PubMed ID: 29763999
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
    Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
    Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
    Schweizer A; Foley JE; Kothny W; Ahrén B
    Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials.
    Chen K; Kang D; Yu M; Zhang R; Zhang Y; Chen G; Mu Y
    Diabetes Obes Metab; 2018 Apr; 20(4):1029-1033. PubMed ID: 29095568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
    Derosa G; Maffioli P
    Diabetes Technol Ther; 2012 Apr; 14(4):350-64. PubMed ID: 22324384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K; Schokker E; Jacob L
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
    Esposito K; Chiodini P; Maiorino MI; Bellastella G; Capuano A; Giugliano D
    BMJ Open; 2014 Jun; 4(6):e005442. PubMed ID: 24916090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
    Ahrén B
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):593-607. PubMed ID: 19046129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing postprandial glucose levels in patients with diabetes.
    Tenzer-Iglesias P; Brunton S
    J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
    Chen C; Yu Q; Zhang S; Yang P; Wang CY
    Int J Clin Exp Pathol; 2015; 8(11):14141-50. PubMed ID: 26823727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A; Ribeiro JP; Casali KR; Schaan BD
    Trials; 2014 Nov; 15():424. PubMed ID: 25366037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.